Literature DB >> 33332284

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.

Camille-Charlotte Balança1, Anna Salvioni1, Clara-Maria Scarlata1,2, Marie Michelas1, Carlos Martinez-Gomez1,3, Carlos Gomez-Roca1,4, Victor Sarradin1,4, Marie Tosolini5, Carine Valle5, Frédéric Pont5, Gwénaël Ferron3, Laurence Gladieff4, Sébastien Vergez6,7, Agnès Dupret-Bories3, Eliane Mery8, Philippe Rochaix8, Jean-Jacques Fournié1, Jean-Pierre Delord1,4,7, Christel Devaud1, Alejandra Martinez1,3, Maha Ayyoub1,2,7.   

Abstract

Tumor antigen-specific CD4 T cells accumulate at tumor sites, evoking their involvement in antitumor effector functions in situ. Contrary to CD8 cytotoxic T lymphocyte exhaustion, that of CD4 T cells remains poorly appreciated. Here, using phenotypic, transcriptomic, and functional approaches, we characterized CD4 T cell exhaustion in patients with head and neck, cervical, and ovarian cancer. We identified a CD4 tumor-infiltrating lymphocyte (TIL) population, defined by high PD-1 and CD39 expression, which contained high proportions of cytokine-producing cells, although the quantity of cytokines produced by these cells was low, evoking an exhausted state. Terminal exhaustion of CD4 TILs was instated regardless of TIM-3 expression, suggesting divergence with CD8 T cell exhaustion. scRNA-Seq and further phenotypic analyses uncovered similarities with the CD8 T cell exhaustion program. In particular, PD-1hiCD39+ CD4 TILs expressed the exhaustion transcription factor TOX and the chemokine CXCL13 and were tumor antigen specific. In vitro, PD-1 blockade enhanced CD4 TIL activation, as evidenced by increased CD154 expression and cytokine secretion, leading to improved dendritic cell maturation and consequently higher tumor-specific CD8 T cell proliferation. Our data identify exhausted CD4 TILs as players in responsiveness to immune checkpoint blockade.

Entities:  

Keywords:  Cancer immunotherapy; Immunology; T cells

Mesh:

Substances:

Year:  2021        PMID: 33332284      PMCID: PMC7934837          DOI: 10.1172/jci.insight.142513

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  34 in total

1.  Comprehensive Integration of Single-Cell Data.

Authors:  Tim Stuart; Andrew Butler; Paul Hoffman; Christoph Hafemeister; Efthymia Papalexi; William M Mauck; Yuhan Hao; Marlon Stoeckius; Peter Smibert; Rahul Satija
Journal:  Cell       Date:  2019-06-06       Impact factor: 41.582

Review 2.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 3.  CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer.

Authors:  Laura M McLane; Mohamed S Abdel-Hakeem; E John Wherry
Journal:  Annu Rev Immunol       Date:  2019-01-24       Impact factor: 28.527

Review 4.  CD4+ T cell help in cancer immunology and immunotherapy.

Authors:  Jannie Borst; Tomasz Ahrends; Nikolina Bąbała; Cornelis J M Melief; Wolfgang Kastenmüller
Journal:  Nat Rev Immunol       Date:  2018-10       Impact factor: 53.106

5.  Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.

Authors:  Ahmed Hamaï; Pascale Pignon; Isabelle Raimbaud; Karine Duperrier-Amouriaux; Hélène Senellart; Sandrine Hiret; Jean-Yves Douillard; Jaafar Bennouna; Maha Ayyoub; Danila Valmori
Journal:  Cancer Res       Date:  2012-01-17       Impact factor: 12.701

6.  CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg.

Authors:  Maha Ayyoub; Pascale Pignon; Jean-Marc Classe; Kunle Odunsi; Danila Valmori
Journal:  Cancer Immunol Res       Date:  2013-08-19       Impact factor: 11.151

7.  IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection.

Authors:  Laura J Pallett; Jessica Davies; Emily J Colbeck; Francis Robertson; Navjyot Hansi; Nicholas J W Easom; Alice R Burton; Kerstin A Stegmann; Anna Schurich; Leo Swadling; Upkar S Gill; Victoria Male; TuVinh Luong; Amir Gander; Brian R Davidson; Patrick T F Kennedy; Mala K Maini
Journal:  J Exp Med       Date:  2017-05-19       Impact factor: 14.307

8.  Simultaneous epitope and transcriptome measurement in single cells.

Authors:  Marlon Stoeckius; Christoph Hafemeister; William Stephenson; Brian Houck-Loomis; Pratip K Chattopadhyay; Harold Swerdlow; Rahul Satija; Peter Smibert
Journal:  Nat Methods       Date:  2017-07-31       Impact factor: 28.547

9.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Authors:  Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; John P Ray; Carl G de Boer; Russell W Jenkins; David J Lieb; Jonathan H Chen; Dennie T Frederick; Michal Barzily-Rokni; Samuel S Freeman; Alexandre Reuben; Paul J Hoover; Alexandra-Chloé Villani; Elena Ivanova; Andrew Portell; Patrick H Lizotte; Amir R Aref; Jean-Pierre Eliane; Marc R Hammond; Hans Vitzthum; Shauna M Blackmon; Bo Li; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; Zachary A Cooper; Cloud P Paweletz; David A Barbie; Anat Stemmer-Rachamimov; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Nir Hacohen
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

10.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.

Authors:  Daniela S Thommen; Viktor H Koelzer; Petra Herzig; Andreas Roller; Marcel Trefny; Sarah Dimeloe; Anna Kiialainen; Jonathan Hanhart; Catherine Schill; Christoph Hess; Spasenija Savic Prince; Mark Wiese; Didier Lardinois; Ping-Chih Ho; Christian Klein; Vaios Karanikas; Kirsten D Mertz; Ton N Schumacher; Alfred Zippelius
Journal:  Nat Med       Date:  2018-06-11       Impact factor: 53.440

View more
  22 in total

1.  Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.

Authors:  Kalika Kamat; Venkatesh Krishnan; Oliver Dorigo
Journal:  Br J Cancer       Date:  2022-06-24       Impact factor: 9.075

2.  Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE2.

Authors:  Qingsheng Li; Kevin E Goggin; SeonYeong Seo; Jonathan M Warawa; Nejat K Egilmez
Journal:  Cancer Immunol Immunother       Date:  2022-09-08       Impact factor: 6.630

3.  A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level.

Authors:  Rita Pfeifer; Janina Henze; Katharina Wittich; Andre Gosselink; Ali Kinkhabwala; Felix Gremse; Cathrin Bleilevens; Kevin Bigott; Melanie Jungblut; Olaf Hardt; Frauke Alves; Wa'el Al Rawashdeh
Journal:  Theranostics       Date:  2022-06-13       Impact factor: 11.600

Review 4.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

5.  Pinpointing the tumor-specific T cells via TCR clusters.

Authors:  Mikhail M Goncharov; Ekaterina A Bryushkova; Nikita I Sharaev; Valeria D Skatova; Anastasiya M Baryshnikova; George V Sharonov; Vadim Karnaukhov; Maria T Vakhitova; Igor V Samoylenko; Lev V Demidov; Sergey Lukyanov; Dmitriy M Chudakov; Ekaterina O Serebrovskaya
Journal:  Elife       Date:  2022-04-04       Impact factor: 8.713

6.  Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function.

Authors:  Joshua R Veatch; Sylvia M Lee; Carolyn Shasha; Naina Singhi; Julia L Szeto; Ata S Moshiri; Teresa S Kim; Kimberly Smythe; Paul Kong; Matthew Fitzgibbon; Brenda Jesernig; Shailender Bhatia; Scott S Tykodi; Evan T Hall; David R Byrd; John A Thompson; Venu G Pillarisetty; Thomas Duhen; A McGarry Houghton; Evan Newell; Raphael Gottardo; Stanley R Riddell
Journal:  Cancer Cell       Date:  2022-04-11       Impact factor: 38.585

Review 7.  CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?

Authors:  Alexandra M Miggelbrink; Joshua D Jackson; Selena J Lorrey; Ethan S Srinivasan; Jessica Waibl-Polania; Daniel S Wilkinson; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2021-06-14       Impact factor: 12.531

8.  Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.

Authors:  Karl L Banta; Xiaozheng Xu; Avantika S Chitre; Amelia Au-Yeung; Chikara Takahashi; William E O'Gorman; Thomas D Wu; Stephanie Mittman; Rafael Cubas; Laetitia Comps-Agrar; Amit Fulzele; Eric J Bennett; Jane L Grogan; Enfu Hui; Eugene Y Chiang; Ira Mellman
Journal:  Immunity       Date:  2022-03-08       Impact factor: 43.474

9.  Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.

Authors:  Lili Song; Shikai Liu; Sufen Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 10.  Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer.

Authors:  Margaux Saillard; Mara Cenerenti; Pedro Romero; Camilla Jandus
Journal:  Vaccines (Basel)       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.